| 1. |
Matsumoto Y, Murata M, Takayama K, Yamasaki S, Hiramine S, Toyoda K, Kibe Y, Nishida R, Kimura S, Sonoda H, Shiose A, Shimono N., A case of mediastinal abscess and infected aortic aneurysm caused by dissemination of Mycobacterium abscessus subsp. massiliense pulmonary disease, J Infect Chemother. 2023 Jan;29(1):82-86. doi: 10.1016/j.jiac.2022.09.017. Epub 2022 Sep 24., 10.1016/j.jiac.2022.09.017. , 29, 1, 82-86, 2023.01. |
| 2. |
Nindita Y, Nakatochi M, Ibusuki R, Shimoshikiryo I, Nishimoto D, Shimatani K, Takezaki T, Ikezaki H, Murata M, Hara M, Nishida Y, Tamura T, Hishida A, Nagayoshi M, Okada R, Matsuo K, Ito H, Mikami H, Nakamura Y, Otani T, Suzuki S, Koyama T, Ozaki E, Kuriki K, Takashima N, Miyagawa N, Arisawa K, Katsuura-Kamano S, Momozawa Y, Kubo M, Takeuchi K, Wakai K., Population-Based Impact of Smoking, Drinking, and Genetic Factors on HDL-cholesterol Levels in J-MICC Study Participants, J Epidemiol. 2023 Apr 5;33(4):193-200. doi: 10.2188/jea.JE20210142. Epub 2022 Feb 22., 10.2188/jea.JE20210142., 33, 4, 193-200, 2023.02. |
| 3. |
Hara M, Nishida Y, Tanaka K, Shimanoe C, Koga K, Furukawa T, Higaki Y, Shinchi K, Ikezaki H, Murata M, Takeuchi K, Tamura T, Hishida A, Tsukamoto M, Kadomatsu Y, Matsuo K, Oze I, Mikami H, Kusakabe M, Takezaki T, Ibusuki R, Suzuki S, Nakagawa-Senda H, Matsui D, Koyama T, Kuriki K, Takashima N, Nakamura Y, Arisawa K, Katsuura-Kamano S, Wakai K., Moderate-to-vigorous Physical Activity and Sedentary Behavior Are Independently Associated With Renal Function: A Cross-sectional Study, J Epidemiol. 2023 Jun 5;33(6):285-293. doi: 10.2188/jea.JE20210155. Epub 2022 Feb 22., 10.2188/jea.JE20210155., 33, 6, 285-293, 2023.02. |
| 4. |
Sasaki K, Murata M, Nakamura K, Matsumoto Y, Nakashima Y, Yamasaki S, Ota A, Hiramine S, Takayama K, Ikezaki H, Toyoda K, Ogawa E, Shimono N., A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy, J Infect Chemother. 2022 Aug;28(8):1208-1211. doi: 10.1016/j.jiac.2022.05.001. Epub 2022 May 11., 10.1016/j.jiac.2022.05.001., 28, 8, 1208-1211, 2022.08. |
| 5. |
Matsunaga T, Kadomatsu Y, Tsukamoto M, Kubo Y, Okada R, Nagayoshi M, Tamura T, Hishida A, Takezaki T, Shimoshikiryo I, Suzuki S, Nakagawa H, Takashima N, Saito Y, Kuriki K, Arisawa K, Katsuura-Kamano S, Kuriyama N, Matsui D, Mikami H, Nakamura Y, Oze I, Ito H, Murata M, Ikezaki H, Nishida Y, Shimanoe C, Takeuchi K, Wakai K., Associations of breastfeeding history with metabolic syndrome and cardiovascular risk factors in community-dwelling parous women: The Japan Multi-Institutional Collaborative Cohort Study, PLoS One. 2022 Jan 19;17(1):e0262252. doi: 10.1371/journal.pone.0262252. eCollection 2022., 10.1371/journal.pone.0262252., 2022.01. |
| 6. |
Fujii R, Hishida A, Nishiyama T, Nakatochi M, Matsuo K, Ito H, Nishida Y, Shimanoe C, Nakamura Y, Turin TC, Suzuki S, Watanabe M, Ibusuki R, Takezaki T, Mikami H, Nakamura Y, Ikezaki H, Murata M, Kuriki K, Kuriyama N, Matsui D, Arisawa K, Katsuura-Kamano S, Tsukamoto M, Tamura T, Kubo Y, Kondo T, Momozawa Y, Kubo M, Takeuchi K, Wakai K., Assessing the Relationship Between High-sensitivity C-reactive Protein and Kidney Function Employing Mendelian Randomization in the Japanese Community-based J-MICC Study, J Epidemiol. 2022 Nov 5;32(11):483-488. doi: 10.2188/jea.JE20200540. Epub 2021 Jul 10., 10.2188/jea.JE20200540., 32, 11, 483-488, 2022.11. |
| 7. |
Ohta A, Ogawa E, Murata M, Matsumoto Y, Yamasaki S, Ikezaki H, Furusyo N., Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication, J Med Virol. 2022 Oct;94(10):5007-5014. doi: 10.1002/jmv.27904. Epub 2022 Jun 11., 10.1002/jmv.27904., 94, 10, 5007-5014, 2022.10. |
| 8. |
Kainuma M, Ouma S, Kawakatsu S, Iritani O, Yamashita KI, Ohara T, Hirano S, Suda S, Hamano T, Hieda S, Yasui M, Yoshiiwa A, Shiota S, Hironishi M, Wada-Isoe K, Sasabayashi D, Yamasaki S, Murata M, Funakoshi K, Hayashi K, Shirafuji N, Sasaki H, Kajimoto Y, Mori Y, Suzuki M, Ito H, Ono K, Tsuboi Y., An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer's disease, Front Pharmacol. 2022 Oct 14;13:991982. doi: 10.3389/fphar.2022.991982. eCollection 2022., 10.3389/fphar.2022.991982., 2022.10. |
| 9. |
Masaki Kakimoto, Masayuki Murata, Fujiko Mitsumoto-Kaseida, Eiichi Ogawa, Yuji Matsumoto, Akira Kusaga, Kazuhiro Toyoda, Takeo Hayashi, Kazuya Ura, Keishi Kanno, Norihiro Furusyo, Susumu Tazuma, Toxocariasis suspected of having infiltrated directly from the liver to the lung through the diaphragm, Internal Medicine, 10.2169/internalmedicine.2716-19, 58, 18, 2737-2741, 2019.09, A 37-year-old woman presented to our hospital with mild abdominal pain experienced for 2 months and hepatic nodules in segments 3 and 8. Peripheral blood eosinophilia was observed, and toxocariasis was serologically diagnosed. Seventeen days after the first imaging evaluation, a new lesion was found in segment 9 of the right lung, which was contiguous through the diaphragm to the hepatic nodule in segment 8. After treatment with albendazole, the liver and lung nodules disappeared. We suspect that larvae had directly invaded the lung from the liver, through the diaphragm.. |
| 10. |
Fujiko Mitsumoto-Kaseida, Masayuki Murata, Koji Takayama, Kazuhiro Toyoda, Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients, Journal of Infection and Chemotherapy, 10.1016/j.jiac.2019.06.003, 26, 1, 28-32, 2020.01, Occult hepatitis B virus (HBV) infection (OBI) is hepatitis B surface antigen (HBsAg) negative but with detectable HBV DNA. Although HIV infection has been reported to be a risk factor for OBI, the prevalence and clinical features of OBI in Japanese HIV infected patients have not been documented. This retrospective, single-center study was conducted to determine the prevalence and characteristic of OBI in Japanese antiretroviral therapy (ART) naïve HIV infected patients. OBI was defined as the presence of serum HBV DNA but without detectable HBsAg. Of the 147 ART naïve HIV infected patients, OBI was detected in 9 (6.1%) patients; 2 (4.3%) of 47 with both anti-HBs and anti-HBc positive, 6 (27.3%) of 22 with anti-HBc alone, and 1 (2.0%) of 50 with both anti-HBs and anti-HBc negative. The mean HBV DNA level was low at 28.7 ± 18.2 IU/mL. The proportion of OBI patients with anti-HBc alone was significantly higher than that of non-OBI patients (66.7% vs 14.5%, P = 0.001). In addition, the prevalence of AIDS (acquired immunodeficiency syndrome)-defining illnesses in the OBI group was significantly higher than in the non-OBI group (77.8% vs 35.5%, P = 0.001). No significant difference was found in the CD4 count or alanine aminotransferase levels of these two groups. This is the first study to reveal the prevalence and clinical features of OBI in Japanese HIV-infected patients. The persistence of anti-HBc alone and AIDS-defining illnesses were associated with the occurrence of OBI in these patients.. |
| 11. |
Kato Y, Furusyo N, Tanaka Y, Yamasaki S, Ueyama T, Takayama K, Mitsumoto-Kaseida F, Murata M, Ikezaki H, Hayashi J, Association of the Serum Endostatin Level, Renal Function, and Carotid Atherosclerosis of Healthy Residents of Japan: Results from the Kyushu and
Okinawa Population Study (KOPS)., J Atheroscler Thromb., 10.5551, 2018.09. |
| 12. |
Tanaka Y, Furusyo N, Kato Y, Ueyama T, Yamasaki S, Ikezaki H, Murata M, Hayashi J, Correlation between Thyroid Stimulating Hormone and Renal Function in Euthyroid Residents of Japan: Results from the Kyushu and Okinawa Population Study (KOPS)., J Atheroscler Thromb., 25, 4, 335-343, 2018.04. |
| 13. |
Ohta A, Furusyo N, Kishihara Y, Eiraku K, Murata M, Kainuma M, Toyoda K, Ogawa E, Hayashi T, Koga T, Secondary Syphilis with Pulmonary Involvement, Intern Med. , 57, 1, 121-126, 2018.01. |
| 14. |
Ikezaki H, Furusyo N, Jacques PF, Shimizu M, Murata M, Schaefer EJ, Urita Y, Hayashi J, Higher dietary cholesterol and ω-3 fatty acid intakes are associated with a lower success rate of Helicobacter pylori eradication therapy in Japan., Am J Clin Nutr. , 106, 2, 581-588, 2017.08. |
| 15. |
Ogawa E, Furusyo N, Murata M, Toyoda K, Hayashi T, Ura K, Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV., Liver Int. , 38, 1, 76-83, 2018.01. |
| 16. |
Tanaka R, Furusyo N, Takeda R, Yamasaki S, Kusaga A, Ogawa E, Murata M, Nakanishi R, Maehara Y, A case of amebiasis with negative serologic markers that caused intra-abdominal abscess., J Infect Chemother. , 23, 11, 778-781, 2017.11. |
| 17. |
Kato Y, Furusyo N, Tanaka Y, Ueyama T, Yamasaki S, Murata M, Hayashi J, The Relation between Serum Endostatin Level and Carotid Atherosclerosis in Healthy Residents of Japan: Results from the Kyushu and Okinawa Population Study
(KOPS)., J Atheroscler Thromb, 24, 10, 1023-1030, 2017.10. |
| 18. |
Fujiko Mitsumoto-Kaseida, Masayuki Murata, Kazuhiro Toyoda, Yuiko Morokuma, Makiko Kiyosuke, DONGCHON KANG, Norihiro Furusyo, Clinical and pathogenic features of SCCmec type II and IV methicillin- resistant Staphylococcus aureus in Japan, JOURNAL OF INFECTION AND CHEMOTHERAPY, 10.1016/j.jiac.2016.11.001, 23, 2, 90-95, 2017.02. |
| 19. |
Fujiko Mitsumoto-Kaseida, Masayuki Murata, Kazuya Ura, Koji Takayama, Satoshi Hiramine, Motohiro Shimizu, Kazuhiro Toyoda, Eiichi Ogawa, Norihiro Furusyo, The Expression Level of Neutrophil CD64 Is a Useful Marker of Systemic Inflammation Associated with HIV Infection, AIDS RESEARCH AND HUMAN RETROVIRUSES, 10.1089/aid.2016.0107, 33, 2, 147-156, 2017.02. |
| 20. |
Eiichi Ogawa, Norihiro Furusyo, Masayuki Murata, Motohiro Shimizu, Kazuhiro Toyoda, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy, ANTIVIRAL THERAPY, 10.3851/IMP3085, 22, 1, 61-70, 2016.09. |
| 21. |
Eri Kumade, Norihiro Furusyo, Norito Takeshima, Yasuhiro Kishihara, Fujiko Mitsumoto-Kaseida, Yoshitaka Eto, Masayuki Murata, Jun Hayashi, A case of lobar pneumonia and sepsis with death caused by invasive Klebsiella rhinoscleromatis infection, J Infect Chemother, 22, 10, 707-711, 2016.10. |
| 22. |
Motohiro Shimizu, Norihiro Furusyo, Yuki Tanaka, Yoshifumi Kato, Mitsumoto-Kaseida Fujiko, Koji Takayama, Kazuya Ura, Satoshi Hiramine, Takeo Hayashi, Hiroaki Ikezaki, Takeshi Ihara, Haru Mukae, Eiichi Ogawa, Kazuhiro Toyoda, Masayuki Murata, Jun Hayashi, The relation of postprandial plasma glucose and serum endostatin to the urinary albumin excretion of residents with prediabetes: results from the Kyushu and Okinawa Population Study (KOPS), International Urology and Nephrology, 48, 6, 851-857, 2016.06. |
| 23. |
Takeo Hayashi, Eiichi Ogawa, Norihiro Furusyo, Masayuki Murata, Jun Hayashi, Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C., Infect Agent Cancer, 10.1186/s13027-016-0056-y, 2016.02. |
| 24. |
Eiichi Ogawa, Norihiro Furusyo, Masayuki Murata, Takeo Hayashi, Motohiro Shimizu, Haru Mukae, Toyoda K, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy, ANTIVIRAL RESEARCH, 10.1016/j.antiviral.2015.12.001, 126, 35-42, 2016.02. |
| 25. |
Hiroaki Ikezaki, Norihiro Furusyo, Satoshi Hiramine, Kazuya Ura, Fujiko Mitsumoto-Kaseida, Koji Takayama, Motohiro Shimizu, Toyoda K, Eiichi Ogawa, M KAINUMA, Masayuki Murata, Jun Hayashi, Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study, ARCHIVES OF VIROLOGY, 10.1007/s00705-015-2703-9, 161, 3, 641-648, 2016.03. |
| 26. |
Kazuya Ura, Norihiro Furusyo, Eiichi Ogawa, Takeo Hayashi, Haru Mukae, Motohiro Shimizu, Toyoda K, Masayuki Murata, Jun Hayashi, Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C, Alimentary Pharmacology and Therapeutics, 43, 1, 114-124, 2016.01. |
| 27. |
Koji Takayama, Norihiro Furusyo, Eiichi Ogawa, Hiroaki Ikezaki, Motohiro Shimizu, Masayuki Murata, Jun Hayashi, Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients, WORLD JOURNAL OF GASTROENTEROLOGY, 10.3748/wjg.v21.i15.4696, 21, 15, 4696-4706, 2015.04. |
| 28. |
Hiroaki Ikezaki, Norihiro Furusyo, Takeshi Ihara, Takeo Hayashi, Kazuya Ura, Satoshi Hiramine, Fujiko Mitsumoto, Koji Takayama, Masayuki Murata, Takuji Kohzuma, Masumi Ai, Emst J. Schaefer, Jun Hayashi, Glycated albumin as a diagnostic tool for diabetes in a general Japanese population, METABOLISM-CLINICAL AND EXPERIMENTAL, 10.1016/j.metabol.2015.03.003, 64, 6, 698-705, 2015.06. |
| 29. |
Fujiko Mitsumoto, Masayuki Murata, kazuya Ura, Koji Takayama, Satoshi Hiramine, Motohiro Shimizu, Toyoda K, Eiichi Ogawa, Norihiro Furusyo, Jun Hayashi, The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients, JOURNAL OF INFECTION AND CHEMOTHERAPY, 10.1016/j.jiac.2014.12.003, 21, 3-4, 264-271, 2015.04. |
| 30. |
迎 はる, 古庄 憲浩, 村田 昌之, 小川 栄一, 貝沼 茂三郎, 志水 元洋, 居原 毅, 林 純, A case of granulomatosis with polyangiitis preceded by subacute thyroiditis., 10.1002/ccr3.181., 3, 3, 139-144, 2015.03. |
| 31. |
志水 元洋, 古庄 憲浩, 池崎 裕昭, 小川 栄一, 林 武生, 居原 毅, 原田 裕士, 豊田 一弘, 村田 昌之, 林 純, Predictors of kidney tubular dysfunction induced by adefovir treatment for
chronic hepatitis B., 10.3748/wjg.v21.i7.2116., 21, 7, 2116-2123, 2015.02. |
| 32. |
志水 元洋, 古庄 憲浩, 光本 富士子, 高山 耕治, 浦 和也, 平峯 智, 池崎 裕昭, 居原 毅, 迎 はる, 小川 栄一, 豊田 一弘, 貝沼 茂三郎, 村田 昌之, 林 純, Subclinical carotid atherosclerosis and triglycerides predict the incidence of
chronic kidney disease in the Japanese general population: results from the
Kyushu and Okinawa Population Study (KOPS)., 238, 2, 207-212, 2015.02. |
| 33. |
光本 富士子, 村田 昌之, 加藤 禎史, 浦 和也, 高山 耕治, 平峯 智, 池崎 裕昭, 志水 元洋, 豊田 一弘, 小川 栄一, 相島 慎一, 古庄 憲浩, 林 純, Hepatitis B virus-related immune reconstitution inflammatory syndrome in two
patients coinfected with human immunodeficiency virus diagnosed with a liver
biopsy., 53, 18, 2165-2170, 2014.09. |
| 34. |
高山 耕治, 古庄 憲浩, 小川 栄一, 志水 元洋, 平峯 智, 光本 富士子, 浦 和也, 豊田 一弘, 村田 昌之, 林 純, A case of successful treatment with telaprevir-based triple therapy for hepatitis
C infection after treatment failure with vaniprevir-based triple therapy., 10.1016/j.jiac.2014.06.002, 20, 9, 577-581, 2014.09. |
| 35. |
貝沼 茂三郎, 古庄 憲浩, 安藤 眞一, 迎 はる, 小川 栄一, 豊田 一弘, 村田 昌之, 林 純, Nocturnal difference in the ultra low frequency band of heart rate variability in
patients stratified by Kampo medicine prescription., 78, 8, 1924-1927, 2014.06. |
| 36. |
村田 昌之, 古庄 憲浩, 小川 栄一, 光本 富士子, 平峯 智, 池崎 裕昭, 高山 耕治, 志水 元洋, 豊田 一弘, 貝沼 茂三郎, 林 純, A case of successful hepatitis C virus eradication by 24 weeks of
telaprevir-based triple therapy for a hemophilia patient with hepatitis C
virus/human immunodeficiency virus co-infection who previously failed pegylated
interferon-α and ribavirin therapy, 10.1016/j.jiac.2013.11.006., 20, 5, 320-324, 2014.05. |
| 37. |
古庄 憲浩, 小川 栄一, 村田 昌之, 豊田 一弘, 大西 八郎, 永樂 訓三, 志水 元洋, 原田 裕士, 光本 富士子, 高山 耕治, 貝沼 茂三郎, 岡田 享子, 林 純, Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological
response., 10.1093/jac/dkt371., 2014.02. |
| 38. |
光本 富士子, 村田 昌之, 加藤 禎史, 浦 和也, 高山 耕治, 平峯 智, 池崎 裕昭, 志水 元洋, 豊田 一弘, 小川 栄一, 相島 慎一, 古庄 憲浩, 林 純, Hepatitis B virus related immune reconstitution inflammatory syndrome, undergone liver biopsy, in two patients coinfected with human immunodeficiency virus, 2014.01. |
| 39. |
居原 毅, 古庄 憲浩, 林 武生, 豊田 一弘, 村田 昌之, 林 純, A population-based epidemiological survey of human parvovirus B19 infection: a
project of the Kyushu and Okinawa Population Study (KOPS)., 10.1007/s00705-013-1746-z., 2013.12. |
| 40. |
小川 栄一, 古庄 憲浩, 村田 昌之, 池崎 裕昭, 居原 毅, 林 武生, 豊田 一弘, 岡田 享子, 貝沼 茂三郎, 梶原 英二, 高橋 和弘, 佐藤 丈顕, 林 純, Valuable antiviral therapeutic options for the treatment of chronic hepatitis C
patients with thrombocytopenia., 10.1111/jvh.12109., 2013.12, Thrombocytopenia in patients with chronic hepatitis C may represent an obstacle
for the initiation of antiviral treatment. The aim of this study was to evaluate
factors predictive of successful pegylated interferon (PEG-IFN) α2b and ribavirin
(RBV) treatment for patients with thrombocytopenia with no history of splenectomy
or partial splenic embolization. One hundred and fifty-one chronic hepatitis C
patients (genotype 1: n = 110, genotype 2: n = 41) with TCP (baseline were enrolled. Pretreatment variables included interleukin 28B (IL28B)
genotype (rs8099917) and homoeostasis model assessment of insulin resistance
score (HOMA-IR). The kinetics of haemoglobin and platelets according to the
inosine triphosphatase (ITPA) genotype (rs1127354) were investigated. Sustained
virological response (SVR) was significantly more frequent in hepatitis C virus
(HCV) genotype 2 (65.9%) than in genotype 1 (34.5%) patients (P Multiple logistic regression analysis of HCV genotype 1 extracted IL28B TT
genotype [odds ratio (OR) 5.97, P = 0.006] and HOMA-IR as significant independent pretreatment predictors of SVR. The analyses of HCV
genotype 2 showed that HOMA-IR was significantly related to SVR, but IL28B
genotype was not. Patients with ITPA CC genotype showed a significant haemoglobin
reduction and lower degree of platelets decrease than those with ITPA CA/AA
genotypes. The most common reason for premature discontinuation of treatment was
the development of hepatocellular carcinoma (n = 8, 5.3%). In conclusion, HOMA-IR
is a useful predictor of SVR for patients with thrombocytopenia infected with HCV
genotype 1 or 2 treated with PEG-IFNα2b and RBV. The inclusion of IL28B, ITPA
genotypes and HOMA-IR adds valuable therapeutic information.. |
| 41. |
村田 昌之, 古庄 憲浩, 小川 栄一, 光本 富士子, 平峯 智, 池崎 裕昭, 高山 耕治, 志水 元洋, 豊田 一弘, 貝沼 茂三郎, 林 純, A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy., doi: 10.1016/j.jiac.2013.11.006., 2013.11, In Japan, the human immunodeficiency virus (HIV) and hepatitis C virus (HCV)
coinfection of some patients with hemophilia was caused by the transfusion of
imported blood products, such as unheated coagulation factor. With the
development of antiretroviral therapy (ART) for HIV, chronic HCV infection has
become a major cause of liver disease and mortality for hemophiliac patients
coinfected with HCV/HIV. Data is limited regarding the efficacy and safety of
antiviral therapy with the HCV protease inhibitor telaprevir (TVR) in combination
with pegylated interferon-α (PegIFN-α) and ribavirin (RBV) for hemophilia
patients coinfected with HCV/HIV. We report a case of a Japanese patient with
hemophilia and HCV/HIV coinfection who had partial response to prior to PegIFN-α
and RBV therapy. This is the first published report of 24-week TVR-based triple
therapy for a hemophilia patient coinfected with HCV/HIV. The patient had HCV
genotype 1a infection with a high viral load. His single-nucleotide polymorphism
of the interleukin 28B (rs8099917) gene was the TT major allele. He presented
with undetectable HIV RNA and a high CD4(+) T cell counts by taking ART including
tenofovir, emtricitabine and raltegravir. He was again treated for HCV with TVR
plus PegIFN-α2b and RBV for the first 12 weeks, followed by the continuation of
PegIFN-α2b and RBV for 12 additional weeks while continuing ART. He had rapid
virological response and achieved sustained virological response with the 24-week
treatment. No serious adverse events such as skin rash, severe anemia or
exacerbated bleeding tendency were observed, only a mild headache. No dose
adjustment was necessary when tenofovir and raltegravir were used in combined
with TVR, and no HIV breakthrough was observed. TVR-based triple therapy with ART
could can an effective treatment for hemophilia patients coinfected with HCV
(genotype 1)/HIV regardless of prior response. TVR can be used in combination
with tenofovir, emtricitabine and raltegravir for patients with hemophilia.
Furthermore, patients with undetectable HCV RNA at week 4 could be successfully
treated with a 24-week regimen.. |
| 42. |
小川 栄一, 古庄 憲浩, 村田 昌之, 豊田 一弘, 永樂 訓三, 志水 元洋, 原田 裕士, 光本 富士子, 高山 耕治, 岡田 享子, 貝沼 茂三郎, 林 純, Early phase viral kinetics of chronic hepatitis C patients receiving
telaprevir-based triple therapy: a comparison of two real-time PCR assays., 10.1016/j.antiviral.2013.05.002., 2013.08. |
| 43. |
谷合 啓明, 古庄 憲浩, 村田 昌之, 光本 富士子, 志水 元洋, 豊田 一弘, 小川 栄一, 貝沼 茂三郎, 岡田 享子, 林 純, A case report of human immunodeficiency virus-associated anaplastic lymphoma
kinase protein-negative anaplastic large cell lymphoma., 10.1186/2193-1801-2-400, 2013.08, Human immunodeficiency virus (HIV)-associated anaplastic large cell lymphoma
(ALCL) is not so common, and anaplastic lymphoma kinase protein (ALK)-negative
ALCL is rare and has a low survival rate. We report a case of a 31-year-old
Japanese man diagnosed with HIV-associated ALK-negative ALCL who presented with
long-lasting fever of unknown origin. The diagnosis was based on a full work-up
that included inguinal lymph-node biopsy. Eight-cycle chemotherapy that included
cyclophosphamide, doxorubicin, vincristine, and prednisone in addition to
antiretroviral therapy for HIV infection provided a complete remission of his
ALCL and over 5-year survival for him.. |
| 44. |
古庄 憲浩, 居原 毅, 林 武生, 池崎 裕昭, 豊田 一弘, 小川 栄一, 岡田 享子, 貝沼 茂三郎, 村田 昌之, 林 純, The serum undercarboxylated osteocalcin level and the diet of a Japanese
population: results from the Kyushu and Okinawa Population Study (KOPS)., 10.1007/s12020-012-9803-z, 2013.06. |
| 45. |
Walaa H Ahmed, 古庄 憲浩, Saad Zaky, Abeer Sharaf Eldin, Hany Aboalam, 小川 栄一, 村田 昌之, 林 純, Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for
predicting anemia in Egyptian hepatitis C virus patients., 10.3748/wjg.v19.i9.1387., 2013.03. |
| 46. |
岡田 享子, 古庄 憲浩, 小川 栄一, 池崎 裕昭, 居原 毅, 林 武生, 貝沼 茂三郎, 村田 昌之, 林 純, Association between chronic hepatitis C virus infection and high levels of
circulating N-terminal pro-brain natriuretic peptide., 10.1007/s12020-012-9688-x., 2013.02. |
| 47. |
古庄 憲浩, 小川 栄一, 須藤 正幸, 村田 昌之, 居原 毅, 池崎 裕昭, 平峯 智, 迎 はる, 豊田 一弘, 谷合 啓明, 岡田 享子, 貝沼 茂三郎, 梶原 英二, 林 純, Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal
women with chronic hepatitis C: a randomized trial., 10.1016/j.jhep.2012.08.003, 2012.12. |
| 48. |
小川 栄一, 古庄 憲浩, 村田 昌之, 池崎 裕昭, 居原 毅, 林 武生, 豊田 一弘, 谷合 啓明, 岡田 享子, 貝沼 茂三郎, 林 純, Insulin resistance undermines the advantages of IL28B polymorphism in the
pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C
patients with genotype 1., 10.1016/j.jhep.2012.04.027, 2012.09. |
| 49. |
岡田 享子, 古庄 憲浩, 村田 昌之, 澤山 泰典, 貝沼 茂三郎, 林 純, A hypertriglyceridemic state increases high sensitivity C-reactive protein of
Japanese men with normal glucose tolerance., 10.1007/s12020-011-9532-8, 2012.02. |
| 50. |
池崎 裕昭, 古庄 憲浩, 居原 毅, 林 武生, 小川 栄一, 豊田 一弘, 谷合 啓明, 貝沼 茂三郎, 村田 昌之, 林 純, Abbott RealTime PCR assay is useful for evaluating virological response to
antiviral treatment for chronic hepatitis C., 10.1007/s10156-011-0249-7, 2011.12. |
| 51. |
小川 栄一, 古庄 憲浩, 村田 昌之, 大西 八郎, 豊田 一弘, 谷合 啓明, 居原 毅, 池崎 裕昭, 林 武生, 貝沼 茂三郎, 林 純, Longitudinal assessment of liver stiffness by transient elastography for chronic
hepatitis B patients treated with nucleoside analog., 10.1111/j.1872-034X.2011.00869.x, 2011.12. |
| 52. |
古庄 憲浩, Walaa H Ahmed, 永樂 訓三, 豊田 一弘, 小川 栄一, 池崎 裕昭, 居原 毅, 林 武生, 貝沼 茂三郎, 村田 昌之, 林 純, Treatment for Eradication of Helicobacter pylori Infection among Chronic
Hepatitis C Patients., 10.5009/gnl.2011.5.4.447, 2011.12. |
| 53. |
Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J., Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients., World J Gastroenterol. 2011 Jun 28;17(24):2945-52., 17, 24, 2945-52, 2011.06, AIM:
To analyze the association between the emergence of tyrosine-methionine-asparatate-asparatate (YMDD) mutants (reverse transcription; rtM204I/V) and deterioration of liver function during long-term lamivudine treatment of Japanese patients with chronic hepatitis B virus (HBV) infection.
METHODS:
The data of 61 consecutive Japanese patients with chronic hepatitis B who underwent continuous lamivudine treatment for more than 24 mo and had a virological response were analyzed. Analysis of YMDD mutants was done by real-time polymerase chain reaction with LightCycler probe hybridization assay for up to 90 mo (mean, 50.8 mo; range, 24-90 mo).
RESULTS:
A mixed mutant-type (YMDD + tyrosine-isoleucine-asparatate-asparatate: YIDD or tyrosine-valine-asparatate-asparatate: YVDD) or a mutant-type (YIDD or YVDD) were found in 57.4% of 61 patients at 1 year, 78.7% of 61 patients at 2 years, 79.6% of 49 patients at 3 years, 70.5% of 34 patients at 4 years, 68.4% of 19 patients at 5 years, 57.1% of 14 patients at 6 years, and 33.3% of 6 patients at 7 years. Of the 61 patients, 56 (92%) had mixed mutant- or a mutant-type. Only 5 (8%) had no mutants at each observation point. Virological breakthrough was found in 26 (46.4%) of 56 patients with YMDD mutants, 20 of whom had a hepatitis flare-up: the remaining 30 (53.6%) had neither a virological breakthrough nor a flare-up. All 20 patients who developed a hepatitis flare-up had a biochemical and virological response after adefovir was added to the lamivudine treatment.
CONCLUSION:
Our results suggest that it is possible to continue lamivudine treatment, even after the emergence of YMDD mutants, up to the time that the patients develop a hepatitis flare-up.. |
| 54. |
古庄 憲浩, 村田 昌之, 小川 栄一, 豊田 一弘, 居原 毅, 池崎 裕昭, 林 武生, 古賀 恒久, 貝沼 茂三郎, 林 純, Ribavirin concentration in the later stages of 48 week pegylated
interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for
predicting virological response., 10.1093/jac/dkr034, 2011.05. |
| 55. |
Masayuki Murata, Norihiro Furusyo, Yayoi Fujimoto, Yoko Kanamoto, Shigeru Otaguro, Eiichi Ogawa, Ryo Yasuhara, Naoko Yamamoto, Jun Hayashi., Evaluation of a New Desktop Washer-Disinfector for the Viral Disinfection of Medical Devices., Japanese Journal of Environmental Infections, 22; 118-21, 2007.06. |
| 56. |
Murata M, Furusyo N, Otaguro S, Nabeshima S, Ariyama I, Hayashi J, HIV Infection with Concomitant Cerebral Toxoplasmosis and Disseminated Histoplasmosis in a 45-Year-Old Man., J Infect Chemother, 13:51-5, 2007.03. |
| 57. |
Murata M, Nabeshima S, Kikuchi K, Yamaji K, Furusyo N, Hayashi J, A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines., Cytokine, 33:121-8, 2006.02. |
| 58. |
Murata M, Kishihara Y, Nabeshima S, Furusyo N, Kuroki M, Hayashi J, Evaluation of a new ozone apparatus, the BOX-O3, for the bacteriological disinfection of medical waste., Japanese society of environmental infections, Vol.19 no.2, 277-80, 2004.01. |
| 59. |
Murata M, Nabeshima S, Maeda N, Nakashima H, Kashiwagi S & Hayashi J., Increased frequency of IFN-g-producing peripheral CD8+ T cells with memory-phenotype in patients with chronic hepatitis C., Journal of medical virology, 10.1002/jmv.2205, 67, 2, 162-170, 67(2):162-70, 2002.01. |
